Bone health in cancer patients: ESMO clinical practice guidelines

Annals of Oncology

Volumn 25, Issue , 2014, Pages 124-137

  Coleman, R ^a   Body, J J ^b   Aapro, M ^c   Hadji, P ^d   Herrstedt, J ^e  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^c Multidisciplinary Oncology Institute   (Switzerland)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RADIOISOTOPE; RADIUM CHLORIDE RA 223; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ADVANCED CANCER; ARTICLE; BONE ATROPHY; BONE DISEASE; BONE HEALTH; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE TURNOVER; BREAST CANCER; BREAST METASTASIS; CANCER INCIDENCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG APPROVAL; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; HEALTH STATUS; HORMONAL THERAPY; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY DISEASE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; OSTEOLYSIS; OSTEOPOROSIS; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL CELL LUNG CANCER; SOLID TUMOR; VITAMIN SUPPLEMENTATION; BONE NEOPLASMS; CANCER STAGING; FOLLOW UP; HEALTH CARE PLANNING; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROGNOSIS; STANDARDS;

BONE NEOPLASMS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASM STAGING; NEOPLASMS; OSTEOPOROSIS; PROGNOSIS; SOCIETIES, MEDICAL;

EID: 84905843716     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu103     Document Type: Article

References (107)

1. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. New Engl J Med 2006; 354: 2250-2261.
2. Kaplan RN, Rafii S, Lyden D. Preparing the 'soil': the premetastatic niche. Cancer Res 2006; 66: 11089-11093.
3. Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: Clinical implications. Breast, 2013; 22: S50-S56.
4. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11: 411-425.
5. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12(Suppl 20): 6243s-6249s.
6. Yong M, Jensen AÖ, Jacobsen JB et al. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 2011; 129: 495-503.
7. Félix J, Andreozzi V, Soares M et al. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health 2011; 14: 499-505.
8. Morrissey C, Roudier MP, Dowell A et al. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castrationresistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res 2013; 28: 333-340.
9. Brown JE, Cook RJ, Major P et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59-69.
10. Decroisette C, Monnet I, Berard H et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol 2011; 6: 576-582.
11. Beuselinck B, Oudard S, Rixe O et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011; 22: 794-800.
12. Melton LJ, III, Kyle RA, Achenbach SJ et al. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005; 20: 487-493.
13. Kanis JA, Johnell O, Oden A et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19: 385-397.
14. Melton LJ, III, Chrischiles EA, Cooper C et al. Perspective: how many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-1010.
15. Kanis JA. On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. WHO Scientific Group Technical Report Technical Report. University of Sheffield, UK. 2007: Printed by the University of Sheffield. https://www.shef.ac.uk/FRAX/pdfs/ WHO_Technical_Report.pdf (24 February 2014, date last accessed).
16. Cummings SR, Browner WS, Bauerx D et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339: 733-738.
17. Siris ES, Miller PD, Barrett-Connor E et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286: 2815-2822.
18. Hadji P, Aapro MS, Body JJ et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011; 22: 2546-2555.
19. Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 2013; 9: 365-374.
20. LeBlanc ES, Nielson CM, Marshall LM, Ueno NT. The effects of serum testosterone, estradiol and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab 2009; 94: 3337-3346.
21. Costelloe CM, Chuang HH, Madewell JE et al. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. J Cancer 2010; 1: 80-92.
22. Coleman RE, Mashiter G, Whitaker KB et al. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 1988; 29: 1354-1359.
23. Coleman R, Costa L, Saad F et al. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol 2011; 80: 411-432.
24. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2005; 2: 504-517.
25. Agarawal JP, Swangsilpa T, van der Linden Y et al. The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol) 2006; 18: 747-760.
26. Lutz S, Chow E. A review of recently published radiotherapy treatment guidelines for bone metastases: contrasts or convergence? J Bone Oncol 2012; 1: 18-23.
27. Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2011; 7: CD003347.
28. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
29. Roelofs AJ, Thompson K, Ebetino FH et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010; 16: 2950-2960.
30. Hortobagyi GN, Theriault RL, Lipton A et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038-2044.
31. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-854.
32. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
33. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744.
34. Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19: 420-432.
35. Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
36. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
37. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
38. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
39. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488-493.
40. McCloskey EV, Maclennan IC, Drayson MT et al. A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 1998; 100: 317-325.
41. Paterson AH, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
42. Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-1137.
43. Barrett-Lee P, Casbard A, Abraham J et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 2014; 15: 114-122.
44. Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-1405.
45. Saad F, Brown JE, Van Poznak C et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347.
46. Coleman RE, de Boer R, Eidtmann H et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405.
47. Coleman RE, Marshall H, Cameron D et al. Breast cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
48. Paterson AH, Anderson SJ, Lembersky BC et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734-742.
49. Powles TJ, Paterson AE, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8: R13.
50. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46.
51. Smith MR, Egerdie B, Hernández Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755.
52. Ellis GK, Bone HG, Chlebowski R et al. Randomised trial of denosumab in patients receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Clin Oncol 2008; 26: 4875-4882.
53. Rhee Y, Song K, Park S et al. Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. Endocr J 2013; 60: 167-172.
54. Van Poznak C, Hannon RA, Mackey JR et al. Prevention of aromatase inhibitor induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28: 967-975.
55. Lester JE, Dodwell D, Purohit OP et al. Prevention of anastozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336-6342.
56. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
57. Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012; 104: 1059-1067.
58. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002; 2: CD002068.
59. Brown JE, Coleman RE. Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol 2012; 9: 110-118.
60. Body JJ, Facon T, Coleman RE et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228.
61. Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-1571.
62. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone 2011; 49: 71-76.
63. Cook RJ, Major P. Multistate analysis of skeletal events in patients with bone metastases. Clin Cancer Res 2006; 12: 6264s-6269s.
64. Cleeland CS, Body JJ, Stopeck A et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013; 119: 832-838.
65. Martin M, Bell R, Bourgeois H et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 2012; 18: 4841-4849.
66. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, doubleblind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
67. Henry D, Vadhan-Raj S, Hirsh V et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 2014; 22: 679-687.
68. Scagliotti GV, Hirsh V, Siena S et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012; 7: 1823-1829.
69. Djulbegovic B, Wheatley K, Ross J et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002; 3: CD003188.
70. Gimsing P, Carlson K, Turesson I et al. Effect of pamidronate 30mg versus 90mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double- blind, randomised controlled trial. Lancet Oncol 2010; 11: 973-982.
71. Morgan GJ, Child JA, Gregory WM et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 2011; 12: 743-752.
72. Morgan GJ, Davies FE, Gregory WM et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-1999.
73. Hageman K, Patel KC, Mace K et al. The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Ann Pharmacother 2013; 47: 1069-1074.
74. Van Poznak CH, Temin S, Yee GC et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bonemodifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221-1227.
75. Amadori D, Aglietta M, Alessi B et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 2013; 14: 663-670.
76. Coleman RE, Wright J, Houston S et al. Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. J Clin Oncol 2012; 30(Suppl 15): abstr 511.
77. Gibiansky L, Sutjandra L, Doshi S et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 2012; 51: 247-260.
78. Kyle RA, Yee GC, Somerfield MR et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25: 2464-2472.
79. Terpos E, Sezer O, Croucher PI et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20: 1303-1317.
80. Terpos E, Morgan G, Dimopoulos MA et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013; 31: 2347-2357.
81. Lacy MQ, Dispenzieri A, Gertz MA et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81: 1047-1053.
82. Lipton A, Fizazi K, Stopeck AT et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-3092.
83. Khosla S, Burr D, Cauley J et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479-1491.
84. Migliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 2011; 7: 34-42.
85. Gnant M, Mlineritsch B, Stoeger H et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 12: 631-641.
86. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res 2011; 71(3 Suppl): S1-S2.
87. Gregory W, Marshall H, Bell R et al. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis. J Clin Oncol 2012; 30 (Suppl 15): abstr 513.
88. Coleman R, Gnant M, Paterson A et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials. In Program and Abstracts of the 2013 San Antonio Breast Cancer Symposium, San Antonio, Texas, 10-14 December 2013. Abstract S4-07, AACR. http:// www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_3045&terms= (17 March 2014, date last accessed).
89. Body JJ, Bergmann P, Boonen S et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer-a consensus paper of the Belgian Bone Club. Osteoporosis Int 2007; 18: 1439-1450.
90. Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34(Suppl 1): S3-S18.
91. Lee CE, Leslie WD, Czaykowski P et al. A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. Curr Oncol 2011; 18: e163-e172.
92. World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX_WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX (17 March 2014, date last accessed).
93. Hadji P, Gnant M, Body JJ et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev 2012; 38: 798-806.
94. Waltman N, Twiss JJ, Ott CD et al. The effects of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. Osteoporos Int 2010; 21: 1361-1369.
95. Tang BM, Eslick GD, Nowson C et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370: 657-666.
96. Shahinian VB, Kuo YF, Freeman JL, Gnant M. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
97. Smith MR, Lee WC, Brandman J et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with non-metastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903.
98. Serpa Neto A, Tobias-Machado M, Esteves MA et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2012; 15: 36-44.
99. Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-1042.
100. Body JJ, Coleman R, Clezardin P et al. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007; 43: 852-858.
101. Compston J, Bowring C, Cooper A et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013; 75: 392-396.
102. Santini D, Fratto ME, Aapro M. Perspectives in the elderly patient: benefits and limits of bisphosphonates and denosumab. Recent Results Cancer Res 2012; 192: 171-185.
103. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009; 69: 73-82.
104. Hadji P, Claus V, Ziller V et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2012; 23: 223-231.
105. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
106. Hadji P, Aapro M, Costa L, Gnant M. Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. Cancer Treat Rev 2012; 38: 815-824.
107. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.